外周血<italic style="font-style: italic">HER</italic>2基因扩增检测（数字PCR法）在抗HER2治疗中的应用共识

卢仁泉; 柳光宇; 杨文涛; 郭林; 关明; 邵志敏; 徐大志; 倪明; 唐峰; 王朝夫; 娄加陶; 孙奋勇; 邢金良; 潘跃银

doi:10.19401/j.cnki.1007-3639.2022.01.012

您当前的位置：

首页 >

文章列表页 >

外周血HER2基因扩增检测（数字PCR法）在抗HER2治疗中的应用共识

指南与共识 | 更新时间：2025-12-31

- 外周血HER2基因扩增检测（数字PCR法）在抗HER2治疗中的应用共识
- Application consensus of peripheral blood HER2 gene amplification detection (digital PCR) in anti-HER2 therapy
- 中国癌症杂志 2022年32卷第1期页码：90-96
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2022.01.012
  中图分类号： R737.9
- 收稿：2021-11-17，
  
  修回：2021-12-29，
  
  纸质出版：2022-01-30
- 稿件说明：
移动端阅览
卢仁泉, 柳光宇, 杨文涛, 等. 外周血HER2基因扩增检测（数字PCR法）在抗HER2治疗中的应用共识[J]. 中国癌症杂志, 2022,32(1):90-96.

Renquan LU, Guangyu LIU, Wentao YANG, et al. Application consensus of peripheral blood HER2 gene amplification detection (digital PCR) in anti-HER2 therapy[J]. China Oncology, 2022, 32(1): 90-96.
卢仁泉, 柳光宇, 杨文涛, 等. 外周血HER2基因扩增检测（数字PCR法）在抗HER2治疗中的应用共识[J]. 中国癌症杂志, 2022,32(1):90-96. DOI： 10.19401/j.cnki.1007-3639.2022.01.012.

Renquan LU, Guangyu LIU, Wentao YANG, et al. Application consensus of peripheral blood HER2 gene amplification detection (digital PCR) in anti-HER2 therapy[J]. China Oncology, 2022, 32(1): 90-96. DOI： 10.19401/j.cnki.1007-3639.2022.01.012.

摘要

Abstract

关键词

Keywords

references

中国医药教育协会乳腺癌个案管理师分会 . 乳腺癌靶向药物静脉输注规范专家共识 [J ] . 中华医学杂志 , 2021 , 101 ( 16 ): 1143 - 1148 .

China Association for Breast Cancer Case Management Division . Consensus on guidelines for intravenous infusion of targeted drugs in breast cancer [J ] . Natl Med J China , 2021 , 101 ( 16 ): 1143 - 1148 .

江泽飞 , 邵志敏 , 徐兵河 . 人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识 [J ] . 中华肿瘤杂志 , 2010 , 32 ( 2 ): 158 - 160 .

JIANG ZEFEI , SHAO ZHIMIN , XU BINGHE . Consensus on clinical diagnosis and treatment of human epidermal growth factor receptor 2 positive breast cancer [J ] . Chin J Oncol , 2010 , 32 ( 2 ): 158 - 160 .

中国临床肿瘤学会乳腺癌专家委员会 , 中国抗癌协会乳腺癌专业委员会 . 人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识(2021版) [J ] . 中华医学杂志 , 2021 , 8 ( 17 ): 1226 - 1231 .

Breast Cancer Expert Committee of Chinese Society of Clinical Oncology , Breast Cancer Professional Committee of Chinese Anti-Cancer Association . Consensus on clinical diagnosis and treatment of human epidermal growth factor receptor 2 positive breast cancer (2021 edition) [J ] . Natl Med J China , 2021 , 8 ( 17 ): 1226 - 1231 .

中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学会乳腺癌诊疗指南2019 [M ] . 北京 : 人民卫生出版社 , 2019 .

Guidelines Working Committee of Chinese Society of Clinical Oncology . The breast cancer guidelines 2019 of Chinese Society of Clinical Oncology [M ] . Beijing : People’s Med Publ House , 2019 .

中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学会乳腺癌诊疗指南2020 [M ] . 北京 : 人民卫生出版社 , 2019 .

Guidelines Working Committee of Chinese Society of Clinical Oncology . The breast cancer guidelines 2020 of Chinese Society of Clinical Oncology [M ] . Beijing : People’s Med Publ House , 2019 .

《乳腺癌 HER 2检测指南(2019版)》编写组 . 乳腺癌 HER 2检测指南(2019版) [J ] . 中华病理学杂志 , 2019 , 48 ( 3 ): 169 - 175 .

Guideline for HER 2 detection of breast cancer (2019 edition) compiling group . Guideline for HER 2 detection of breast cancer (2019 edition)(2019版) [J ] . Chin J Pathol , 2019 , 48 ( 3 ): 169 - 175 .

WOLFF A C , HAMMOND M E H , ALLISON K H , et al. HER 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update summary [J ] . J Oncol Pract , 2018 , 14 ( 7 ): 437 - 441 . DOI: 10.1200/JOP.18.00206 http://doi.org/10.1200/JOP.18.00206 https://ascopubs.org/doi/10.1200/JOP.18.00206 https://ascopubs.org/doi/10.1200/JOP.18.00206

张众 , 王华新 , 谢丰培 . 乳腺癌异质性及其临床意义 [J ] . 临床与实验病理学杂志 , 2014 , 30 ( 5 ): 473 - 477 .

ZHANG Z , WANG H X , XIE F P . Heterogeneity of breast cancer and its clinical significance [J ] . Chin J Clin Exp Pathol , 2014 , 30 ( 5 ): 473 - 477 .

王歆光 , 刘毅强 , 何英剑 , 等 . 同侧多原发灶乳腺癌病灶间异质性的研究 [J ] . 中国癌症杂志 , 2017 , 27 ( 10 ): 809 - 814 .

WANG X G , LIU Y Q , HE Y J , et al. Intertumoral heterogeneity in patients with ipsilateral multifocal/multicentric breast cancer diagnosed by core needle biopsy [J ] . China Oncol , 2017 , 27 ( 10 ): 809 - 814 .

LOWER E E , GLASS E , BLAU R , et al. HER-2/neu expression in primary and metastatic breast cancer [J ] . Breast Cancer Res Treat , 2009 , 113 ( 2 ): 301 - 306 . DOI: 10.1007/s10549-008-9931-6 http://doi.org/10.1007/s10549-008-9931-6 http://link.springer.com/10.1007/s10549-008-9931-6 http://link.springer.com/10.1007/s10549-008-9931-6

HYUN C L , LEE H E , KIM K S , et al. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer [J ] . J Clin Pathol , 2007 , 61 ( 3 ): 317 - 321 . DOI: 10.1136/jcp.2007.050336 http://doi.org/10.1136/jcp.2007.050336 http://jcp.bmj.com/cgi/doi/10.1136/jcp.2007.050336 http://jcp.bmj.com/cgi/doi/10.1136/jcp.2007.050336

DAWSON S J , TSUI D W , MURTAZA M , et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer [J ] . N Engl J Med , 2013 , 368 ( 13 ): 1199 - 1209 . DOI: 10.1056/NEJMoa1213261 http://doi.org/10.1056/NEJMoa1213261 http://www.nejm.org/doi/10.1056/NEJMoa1213261 http://www.nejm.org/doi/10.1056/NEJMoa1213261

中国抗癌协会肿瘤标志专业委员会遗传性肿瘤标志物协作组 , 中国抗癌协会肿瘤标志专业委员会乳腺癌标志物协作组 . 复发/转移性乳腺癌标志物临床应用专家共识(2019年版) [J ] . 中国癌症防治杂志 , 2019 , 11 ( 5 ): 363 - 374 .

Genetic Tumor Markers Collaborative Group of Tumor Markers Professional Committee of China Anti-Cancer Association , Breast Cancer Markers Collaborative Group of Tumor Markers Professional Committee of China Anti-Cancer Association . Expert consensus on clinical application of markers for recurrent/metastatic breast cancer (2019 edition) [J ] . Chin J of Oncol Prev and Treat , 2019 , 11 ( 5 ): 363 - 374 .

徐兵河 , 王树森 , 江泽飞 , 等 . 中国晚期乳腺癌维持治疗专家共识 [J ] . 中华医学杂志 , 2018 , 98 ( 2 ): 87 - 90 .

XU B H , WANG S S , JIANG Z F , et al. Expert consensus on maintenance therapy for advanced breast cancer in China [J ] . Natl Med J China , 2018 , 98 ( 2 ): 87 - 90 .

ZHOU R F , YUAN P , ZHANG L H , et al. Using digital PCR to detect HER2 amplification in breast and gastric cancer patients [J ] . Front Lab Med , 2018 , 2 ( 3 ): 102 - 108 . DOI: 10.1016/j.flm.2018.11.002 http://doi.org/10.1016/j.flm.2018.11.002 https://linkinghub.elsevier.com/retrieve/pii/S2542364918300657 https://linkinghub.elsevier.com/retrieve/pii/S2542364918300657

WHALE A S , HUGGETT J F , COWEN S , et al. Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation [J ] . Nucleic Acids Res , 2012 , 40 ( 11 ): e82 . DOI: 10.1093/nar/gks203 http://doi.org/10.1093/nar/gks203 https://academic.oup.com/nar/article/40/11/e82/2409772 https://academic.oup.com/nar/article/40/11/e82/2409772

母予馨 , 张频 , 马飞 , 等 . 乳腺癌原发灶和转移灶受体表达的异质性及其临床意义 [J ] . 中华肿瘤杂志 , 2018 , 40 ( 7 ): 506 - 511 .

MU Y X , ZHANG P , MA F , et al. Heterogeneity of receptor expression in primary and metastatic breast cancer and its clinical significance [J ] . Chin J Oncol , 2018 , 40 ( 7 ): 506 - 511 .

YI Z B , YU P , ZHANG S , et al. Profile and outcome of receptor conversion in breast cancer metastases: a nation-wide multicenter epidemiological study [J ] . Int J Cancer , 2021 , 148 ( 3 ): 692 - 701 . DOI: 10.1002/ijc.v148.3 http://doi.org/10.1002/ijc.v148.3 https://onlinelibrary.wiley.com/toc/10970215/148/3 https://onlinelibrary.wiley.com/toc/10970215/148/3

MA C X , BOSE R , GAO F , et al. Neratinib efficacy and circulating tumor DNA detection of HER 2 mutations in HER2 nonamplified metastatic breast cancer [J ] . Clin Cancer Res , 2017 , 23 ( 19 ): 5687 - 5695 . DOI: 10.1158/1078-0432.CCR-17-0900 http://doi.org/10.1158/1078-0432.CCR-17-0900 http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-17-0900 http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-17-0900

MA F , ZHU W J , GUAN Y F , et al. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy [J ] . Oncotarget , 2016 , 7 ( 40 ): 66020 - 66031 . DOI: 10.18632/oncotarget.v7i40 http://doi.org/10.18632/oncotarget.v7i40 https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.v7i40 https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.v7i40

GUAN X , LIU B , NIU Y , et al. Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer [J ] . Breast , 2020 , 49 : 261 - 266 . DOI: 10.1016/j.breast.2019.12.010 http://doi.org/10.1016/j.breast.2019.12.010 https://linkinghub.elsevier.com/retrieve/pii/S0960977619312172 https://linkinghub.elsevier.com/retrieve/pii/S0960977619312172

中国临床肿瘤学会抗肿瘤药物安全管理专家委员会 , 中国抗癌协会胃癌专业委员会 , 中国抗癌协会肿瘤病理专业委员会 . HER2阳性晚期胃癌分子靶向治疗的中国专家共识(2016版) [J ] . 临床肿瘤学杂志 , 2016 , 21 ( 9 ): 831 - 389 .

Expert Committee on Safety Management of Anti-Tumor Drugs of Chinese Society of Clinical Oncology , Gastric Cancer Professional Committee of China Anti-Cancer Association , Tumor Pathology Professional Committee of China Anti-Cancer Association . Chinese expert consensus on molecular targeted t her apy for HER2 positive advanced gastric cancer (2016 edition) [J ] . Chin Clin Oncol , 2016 , 21 ( 9 ): 831 - 389 .

BANG Y J , VAN CUTSEM E , FEYEREISLOVA A , et al. Trastuzumab in combination with chemotherapy versus chemot her apy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [J ] . Lancet , 2010 , 376 ( 9742 ): 687 - 697 . DOI: 10.1016/S0140-6736(10)61121-X http://doi.org/10.1016/S0140-6736(10)61121-X https://linkinghub.elsevier.com/retrieve/pii/S014067361061121X https://linkinghub.elsevier.com/retrieve/pii/S014067361061121X

TSURUTANI J , IWATA H , KROP I , et al. Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase Ⅰ study in multiple advanced solid tumors [J ] . Cancer Discov , 2020 , 10 ( 5 ): 688 - 701 . DOI: 10.1158/2159-8290.CD-19-1014 http://doi.org/10.1158/2159-8290.CD-19-1014 http://cancerdiscovery.aacrjournals.org/lookup/doi/10.1158/2159-8290.CD-19-1014 http://cancerdiscovery.aacrjournals.org/lookup/doi/10.1158/2159-8290.CD-19-1014

HURVITZ S A , MARTIN M , SYMMANS W F , et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial [J ] . Lancet Oncol , 2018 , 19 ( 1 ): 115 - 126 . DOI: 10.1016/S1470-2045(17)30716-7 http://doi.org/10.1016/S1470-2045(17)30716-7 https://linkinghub.elsevier.com/retrieve/pii/S1470204517307167 https://linkinghub.elsevier.com/retrieve/pii/S1470204517307167

浏览量

3103

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

中国乳腺癌患者BRCA1/2基因检测与临床应用专家共识（2025年版）

化疗相关腹泻全程管理中国专家共识（2025年版）

2024年度晚期乳腺癌共识与争议的现状及展望

2024年改变早期乳腺癌临床实践的重要研究成果及进展

中国尿路上皮癌患者HER2表达及其与临床病理学特征的关联分析

外周血HER2基因扩增检测（数字PCR法）在抗HER2治疗中的应用共识

Application consensus of peripheral blood HER2 gene amplification detection (digital PCR) in anti-HER2 therapy

DOI：10.19401/j.cnki.1007-3639.2022.01.012

摘要

Abstract

关键词

Keywords

references